Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis

Michael R. Robinson, Chi Chao Chan, James C. Yang, Benjamin I. Rubin, Gerald J. Gracia, H. Nida Sen, Karl G. Csaky, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.

Original languageEnglish (US)
Pages (from-to)478-479
Number of pages2
JournalJournal of Immunotherapy
Volume27
Issue number6
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

CTLA-4 Antigen
Uveitis
Melanoma
Monoclonal Antibodies
Autoimmune Diseases
Melanoma-Specific Antigens
T-Lymphocytes
Cancer Vaccines
Melanocytes
Differentiation Antigens
Animal Models
Maintenance
Antigens
Neoplasms

Keywords

  • Autoimmunity
  • CTLA-4 antibody
  • Immunotherapy
  • Melanoma
  • Uveitis

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Robinson, M. R., Chan, C. C., Yang, J. C., Rubin, B. I., Gracia, G. J., Sen, H. N., ... Rosenberg, S. A. (2004). Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis. Journal of Immunotherapy, 27(6), 478-479.

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma : A new cause of uveitis. / Robinson, Michael R.; Chan, Chi Chao; Yang, James C.; Rubin, Benjamin I.; Gracia, Gerald J.; Sen, H. Nida; Csaky, Karl G.; Rosenberg, Steven A.

In: Journal of Immunotherapy, Vol. 27, No. 6, 11.2004, p. 478-479.

Research output: Contribution to journalArticle

Robinson, MR, Chan, CC, Yang, JC, Rubin, BI, Gracia, GJ, Sen, HN, Csaky, KG & Rosenberg, SA 2004, 'Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis', Journal of Immunotherapy, vol. 27, no. 6, pp. 478-479.
Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis. Journal of Immunotherapy. 2004 Nov;27(6):478-479.
Robinson, Michael R. ; Chan, Chi Chao ; Yang, James C. ; Rubin, Benjamin I. ; Gracia, Gerald J. ; Sen, H. Nida ; Csaky, Karl G. ; Rosenberg, Steven A. / Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma : A new cause of uveitis. In: Journal of Immunotherapy. 2004 ; Vol. 27, No. 6. pp. 478-479.
@article{79ad48d9d5af4c53ae91530f49dd9670,
title = "Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis",
abstract = "Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.",
keywords = "Autoimmunity, CTLA-4 antibody, Immunotherapy, Melanoma, Uveitis",
author = "Robinson, {Michael R.} and Chan, {Chi Chao} and Yang, {James C.} and Rubin, {Benjamin I.} and Gracia, {Gerald J.} and Sen, {H. Nida} and Csaky, {Karl G.} and Rosenberg, {Steven A.}",
year = "2004",
month = "11",
language = "English (US)",
volume = "27",
pages = "478--479",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

T2 - A new cause of uveitis

AU - Robinson, Michael R.

AU - Chan, Chi Chao

AU - Yang, James C.

AU - Rubin, Benjamin I.

AU - Gracia, Gerald J.

AU - Sen, H. Nida

AU - Csaky, Karl G.

AU - Rosenberg, Steven A.

PY - 2004/11

Y1 - 2004/11

N2 - Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.

AB - Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis. This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.

KW - Autoimmunity

KW - CTLA-4 antibody

KW - Immunotherapy

KW - Melanoma

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=7444262481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444262481&partnerID=8YFLogxK

M3 - Article

C2 - 15534492

AN - SCOPUS:7444262481

VL - 27

SP - 478

EP - 479

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -